NASDAQ · NRSN
Healthcare · Biotechnology
$1.99
Down-$0.14 (-6.57%)
Updated Nov 1, 2026, 6:41 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NRSN
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
NRSN closed at $1.99 after 20 trading sessions, down 50.62% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $2.20 | $2.22 | $1.99 | $1.99 | 20.18K |
| Oct 29, 2026 | $2.302 | $2.32 | $2.0902 | $2.13 | 20.58K |
| Oct 28, 2026 | $2.33 | $2.37 | $2.20 | $2.36 | 17.3K |
| Oct 27, 2026 | $2.30 | $2.5999 | $2.28 | $2.37 | 22.27K |
| Oct 26, 2026 | $2.4664 | $2.75 | $2.31 | $2.33 | 29.71K |
| Oct 23, 2026 | $2.49 | $2.55 | $2.40 | $2.46 | 11.15K |
| Oct 22, 2026 | $2.55 | $2.5699 | $2.15 | $2.44 | 18.6K |
| Oct 21, 2026 | $2.46 | $2.70 | $2.4101 | $2.56 | 11.27K |
| Oct 20, 2026 | $2.74 | $2.74 | $2.19 | $2.39 | 13.85K |
| Oct 19, 2026 | $2.94 | $2.94 | $2.3586 | $2.665 | 117.6K |
| Oct 16, 2026 | $3.06 | $3.24 | $3.06 | $3.07 | 9.7K |
| Oct 15, 2026 | $3.08 | $3.2608 | $2.87 | $3.17 | 11.86K |
| Oct 14, 2026 | $3.56 | $3.60 | $3.05 | $3.06 | 30.84K |
| Oct 13, 2026 | $3.7744 | $3.784 | $3.365 | $3.49 | 43.22K |
| Oct 12, 2026 | $3.66 | $3.66 | $3.28 | $3.48 | 7.42K |
| Oct 9, 2026 | $3.6135 | $3.85 | $3.6135 | $3.66 | 15.61K |
| Oct 8, 2026 | $3.82 | $3.8979 | $3.561 | $3.58 | 15.85K |
| Oct 7, 2026 | $3.95 | $4.07 | $3.79 | $3.82 | 12.89K |
| Oct 6, 2026 | $4.03 | $4.33 | $3.94 | $4.07 | 17.78K |
| Oct 5, 2026 | $4.06 | $4.54 | $3.96 | $4.03 | 12.25K |
The latest Smart Investors Daily articles mentioning NRSN.
Company
Market Activity
Research & News
NRSN research
Company profile and research snapshot.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 28, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 3, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 8, 2026 | D. Boral Capital | Buy | — |
| Mar 25, 2026 | D. Boral Capital | Buy | — |
| Mar 17, 2026 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 10, 2026
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $3.
Benzinga · Feb 18, 2026
Benzinga · Feb 18, 2026
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the
Yahoo · Feb 9, 2026
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Australian Patent Office (IP Australia) has granted Australian Patent No. 2022370513, entitled "Compositions Comprising Ciprofloxacin and Celecoxib," representing another strategic step in the continued expansion of the Company's global intellectual property protection for PrimeC.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NRSN.
